MPM BioImpact’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,370,982
| Closed | -$5.06M | – | 39 |
|
|
2023
Q1 | $5.06M | Hold |
3,370,982
| – | – | 1.31% | 21 |
|
|
2022
Q4 | $3.37M | Hold |
3,370,982
| – | – | 0.87% | 25 |
|
|
2022
Q3 | $6.07M | Hold |
3,370,982
| – | – | 1.44% | 19 |
|
|
2022
Q2 | $9.8M | Hold |
3,370,982
| – | – | 2.72% | 9 |
|
|
2022
Q1 | $9.3M | Hold |
3,370,982
| – | – | 2.5% | 10 |
|
|
2021
Q4 | $15.7M | Hold |
3,370,982
| – | – | 2.86% | 9 |
|
|
2021
Q3 | $28.7M | Hold |
3,370,982
| – | – | 4.45% | 6 |
|
|
2021
Q2 | $55.3M | Hold |
3,370,982
| – | – | 9.09% | 3 |
|
|
2021
Q1 | $74.4M | Hold |
3,370,982
| – | – | 9.35% | 4 |
|
|
2020
Q4 | $104M | Hold |
3,370,982
| – | – | 18.31% | 1 |
|
|
2020
Q3 | $68.5M | Hold |
3,370,982
| – | – | 16.5% | 2 |
|
|
2020
Q2 | $51.8M | Hold |
3,370,982
| – | – | 13.77% | 3 |
|
|
2020
Q1 | $26.1M | Hold |
3,370,982
| – | – | 15.94% | 3 |
|
|
2019
Q4 | $48.1M | Buy |
+3,370,982
| New | +$52.1M | 17.06% | 3 |
|
MPM BioImpact's TCRR Position: Q2 2023 in Review
MPM BioImpact sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 3,370,982 shares — an estimated $5.06M sold.
MPM BioImpact first reported a position in TCRR in Q4 2019 and held it in 14 quarters. The position peaked at $104M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- MPM BioImpact reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- MPM BioImpact sold 3,370,982 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $5.06M.
- MPM BioImpact first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- MPM BioImpact's TCR2 Therapeutics Inc. Common Stock position peaked at $104M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.